The WTA is moving forward with a new eligibility policy this month that mandates genetic screenings for all players to detect the SRY gene. This one-time test marks a shift in how the tour approaches biological sex criteria, aiming to preserve fairness in professional competition. While the organization maintains that the policy promotes equal athletic opportunities, the rollout has drawn criticism regarding its necessity and the manner in which it was introduced.
Players are now reacting to the change as the mandate takes effect. Coco Gauff recently shared her perspective at the National Bank Open, noting that communication between the tour and the players could have been more transparent. Many athletes reportedly learned of the requirement only after the official public release on July 20. Gauff expressed a desire to balance support for the trans community with the goal of ensuring fairness for women in sport.
Other high-profile players have shared varying views on the subject. Belinda Bencic stated her support for the policy, noting her satisfaction with the decision. Meanwhile, Jessica Pegula mentioned that the update appears to be a response to standards seen in other sporting organizations, though she noted a lack of vocal opposition from the player council thus far. Elena Rybakina suggested the sport functioned adequately without the tests, though she indicated a willingness to comply with the new mandate.
Gauff emphasized that the public discourse surrounding this topic often invites misinformation and hostility. She acknowledged the difficulty of navigating these conversations without the risk of social media backlash. As the tour prepares for upcoming tournaments, the conversation among athletes remains divided between those who see the test as a necessary evolution of sporting rules and those who worry about the impact on the community.